Further research and clinical trials are warranted to understand better the complex role of CXCR4 (particularly the expression of the ligand-activated p S339 form of CXCR4) in cancer progression and to explore potential strategies for the effective therapeutic targeting of this axis in different tumor types, including GBC. Here, CXCR4 is linked to cancer.